Aevi Genomic Medicine (NASDAQ: GNMX) is one of 85 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Aevi Genomic Medicine to similar businesses based on the strength of its earnings, risk, analyst recommendations, dividends, institutional ownership, profitability and valuation.
Insider & Institutional Ownership
20.8% of Aevi Genomic Medicine shares are held by institutional investors. Comparatively, 22.3% of shares of all “Biotechnology” companies are held by institutional investors. 15.2% of Aevi Genomic Medicine shares are held by company insiders. Comparatively, 17.9% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Risk and Volatility
Aevi Genomic Medicine has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Aevi Genomic Medicine’s competitors have a beta of 3.27, suggesting that their average stock price is 227% more volatile than the S&P 500.
This is a breakdown of recent ratings and recommmendations for Aevi Genomic Medicine and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aevi Genomic Medicine||0||1||1||0||2.50|
|Aevi Genomic Medicine Competitors||119||408||991||10||2.58|
Aevi Genomic Medicine presently has a consensus target price of $4.25, suggesting a potential upside of 172.44%. As a group, “Biotechnology” companies have a potential upside of 46.91%. Given Aevi Genomic Medicine’s higher possible upside, analysts clearly believe Aevi Genomic Medicine is more favorable than its competitors.
Earnings and Valuation
This table compares Aevi Genomic Medicine and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Aevi Genomic Medicine||N/A||-$41.90 million||-1.62|
|Aevi Genomic Medicine Competitors||$399.82 million||$59.34 million||-6.70|
Aevi Genomic Medicine’s competitors have higher revenue and earnings than Aevi Genomic Medicine. Aevi Genomic Medicine is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares Aevi Genomic Medicine and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aevi Genomic Medicine||N/A||-138.84%||-115.22%|
|Aevi Genomic Medicine Competitors||-853.45%||-188.65%||-26.86%|
Aevi Genomic Medicine competitors beat Aevi Genomic Medicine on 9 of the 12 factors compared.
Aevi Genomic Medicine Company Profile
Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.
What are top analysts saying about Aevi Genomic Medicine Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aevi Genomic Medicine Inc. and related companies.